Business Wire

MITSUBISHI-ENG-PLASTICS

1.6.2021 03:02:05 CEST | Business Wire | Press release

Share
Mitsubishi Engineering-Plastics Has Developed a Medical Grade Polyacetal Resin, the "Iupital (TM) MA Series"

Mitsubishi Engineering-Plastics Corporation (MEP), a world leader in high-performance polyacetal materials, has developed a new polyacetal resin (POM), the Iupital MA Series, that is compliant with medical standards.

The MA series is available in a range of standard, high-flow, high-rigidity, and low-friction grades, enabling greater design flexibility for medical devices and equipment, which are becoming smaller and lighter.

In particular, the low-friction grade MAL20 has greatly improved sliding performance with POM. In the past, combining POM parts would generate squeaking noise and friction, so designs would combine different materials in order to avoid these issues. MAL20 suppresses friction and wear, even when combined with ordinary POM, achieving quiet, smooth movement, which greatly improves comfort when used in medical devices.

In addition, with the MA series, we will offer a coloring masterbatch for color mixing. We support parts design not only in terms of physical characteristics, but also in terms of visual design.

MEP Vice President, Katsushige Hayashi, said the following. "These new materials, which exhibit a variety of excellent properties, will expand the range of designs, especially for medical devices and instruments, and contribute to improving their functionality. In particular, the sliding grade MAL20 eliminates the discomfort caused by noise and friction due to contact between POMs, providing users with comfort and ease of use."

The Iupital MA series meets the quality and regulatory requirements for medical materials, and is suitable for applications such as drug inhalers for COPD and asthma, injection devices such as insulin pens, and parts for medical devices.

Overview of Mitsubishi Engineering-Plastics Corporation

  1. Headquarters: Minato-ku, Tokyo
  2. Branches: Osaka Branch (Osaka, Osaka Prefecture), Nagoya Branch (Nagoya, Aichi Prefecture)
  3. Technical Base: Technical Center (Hiratsuka, Kanagawa Prefecture)
  4. President: Takashi Komaya
  5. Capital: 3 billion yen (50% invested by each of Mitsubishi Gas Chemical Company, Inc. and Mitsubishi Chemical Corporation)

Basic Information on the Iupital ™ MA Series

Features

  • We offer a variety of grade groups in addition to the standard grades, including high flow, high rigidity, and low friction
  • Masterbatch coloring available
  • Worldwide sales and technical support

Grade Lineup

  • MAS20 Standard: This is the grade with the most common physical properties and flowability
  • MAS30 High flow: This grade has increased flowability. Suitable for precision molding
  • MAH25 High rigidity: This grade has increased rigidity and strength. Suitable for making thinner walls and increasing strength
  • MAL20 Low-friction: This grade has excellent sliding characteristics. It contributes to low-noise designs with low sliding resistance

Supported Standards, Etc.

  • ISO10993-5, 10
  • USP [87]
  • USP [88] Class IV
  • FDA Drug Master File

For data on physical properties, etc., please download it from our website, or contact our sales staff at the nearest head office, branch office, or local subsidiary.

Basic Physical Properties Charts

https://www.m-ep.co.jp/ja/eve/18-2.html (Japanese)
https://www.m-ep.co.jp/en/eve/18-2.html (English)
https://www.m-ep.co.jp/ch/eve/18-2.html (Chinese)

Sales Bases

https://www.m-ep.co.jp/company/kaigai.html (Japanese)
https://www.m-ep.co.jp/en/company/kaigai.html (English)
https://www.m-ep.co.jp/ch/company/kaigai.html (Chinese)

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye